- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04966585
Pilot Study of Posaconazole in Crohn's Disease
A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Melissa Hampton
- Phone Number: 310-423-0035
- Email: melissa.hampton@cshs.org
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center (CSMC)
-
-
Minnesota
-
Rochester, Minnesota, United States, 55901
- Recruiting
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients aged 18 years and older, inclusive based on the date of the screening visit.
- A diagnosis of CD with minimum disease duration of 6 months with involvement of the ileum and/or colon documented on colonoscopy
- Have an endoscopically-confirmed active Crohn's disease with active disease defined by SES-CD > 6 (>4 if ileal only), AND active symptoms of Crohn's disease (CDAI score >220)
- Homozygous for CARD9 S12N risk allele, without the protective exon 11 polymorphism
- Subjects receiving oral aminosalicylates (at a stable dose for 2 weeks prior to baseline), immunomodulators (at a stable dose for 4 weeks prior to baseline), anti-TNF, anti IL12/23, or anti-integrin therapy (at stable maintenance doses for > 8 weeks) may continue their use during the study.
- Subjects receiving oral corticosteroids may continue their use during the study provided the dose (prednisone up to 20 mg/day, budesonide up to 9 mg/day) has been stable for two weeks prior to screening.
- Have had age-appropriate and disease-duration-appropriate colon cancer screening1 without unresected dysplasia.
- Women of childbearing age, excluding those with prior bilateral tubal ligation or at least one-year post-menopause, must not be pregnant, lactating, or planning to become pregnant. They must agree to use effective contraception throughout the study period.
- Subjects must be able to provide informed consent and understand, agree with, and be able to adhere to daily diary entries, all scheduled visits, tests, procedures, and protocol in English.
Exclusion Criteria:
- Known hypersensitivity or allergy to posaconazole or other azole antifungal agents
- Concomitant medications primarily metabolized by CY3PA4 including: a) Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, primarily metabolized by CY3PA4 (increases risk of rhabdomyolysis), b) Sirolimus, c) Ergot alkaloids, d) vincristine
- Proarrhythmic conditions
- Moderate or severe renal impairment (Cr Clearance <50)
- Current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, infectious colitis, or microscopic colitis.
- Fulminant colitis, toxic megacolon, peritonitis, ileostomy or colostomy.
- Stool sample positive for pathogens including ova and parasites, Salmonella, Shigella, and C. difficile at screening.
- History of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease or any other medical condition that, in the Investigators opinion, would prevent the subject from participation in the study.
- Treatment with antibiotics, antifungal agents, probiotics, or prebiotics within two weeks of screening.
- Alcohol or drug abuse (in the opinion of the Investigator) that would interfere with compliance.
- Any other investigational therapy or treatment within four weeks of screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
|
Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day.
Duration of therapy will be 12 weeks.
|
Experimental: Posaconazole
Subjects administered posaconazole (Noxafil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
|
Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day.
Duration of therapy will be 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endoscopic Response
Time Frame: Week 12
|
Defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD).
The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings.
The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum.
Scores range from 0 to 60, with higher scores indicating more severe disease.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Week 12
|
Week 12
|
|
Induction of Clinical Remission
Time Frame: Week 12
|
Defined as Patient-Reported Outcome (PRO2) abdominal pain score ≤1 AND stool frequency ≤3, and Crohn's Disease Activity Index (CDAI) (<150). PRO2 is the weighted average of the 2 variables of frequency of liquid or very soft stool and abdominal pain, based on 7-day participant diary data. The PRO2 score has a minimum score of 0 and has no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity. |
Week 12
|
Change in amount of concomitant medications
Time Frame: Week 12
|
Week 12
|
|
Proportion of subjects in endoscopic remission
Time Frame: Week 12
|
Defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) score of ≤3.
The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings.
The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum.
Scores range from 0 to 56, with higher scores indicating more severe disease.
|
Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gil Y Melmed, MD, Cedars-Sinai Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- 14-alpha Demethylase Inhibitors
- Trypanocidal Agents
- Posaconazole
Other Study ID Numbers
- MOD03104
- 1R01DK125495-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Posaconazole Delayed Release Oral Tablet
-
Neuroscience Trials AustraliaThe Florey Institute of Neuroscience and Mental HealthActive, not recruitingMild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's DiseaseAustralia
-
BayerCompletedRenal Impairment | Chronic Kidney Disease | Healthy VolunteersGermany
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...Active, not recruitingProstate CancerUnited States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Synthetic Biologics Inc.Spaulding Clinical Research LLCCompletedEnteritis Caused by RadiationUnited States
-
AstraZenecaParexelCompleted
-
Napo Pharmaceuticals, Inc.CompletedAcquired Immunodeficiency Syndrome | HIV/AIDS | Healthy Volunteers | Human Immunodeficiency Virus | HIV DiarrheaUnited States
-
ApoPharmaAlgorithme Pharma IncCompleted
-
Ain Shams Maternity HospitalCompletedGastrointestinal Motility and Defaecation ConditionsEgypt
-
HALEONCompletedGastrointestinal DiseasesCanada